124 results on '"Colicchio, Salvatore"'
Search Results
2. Sensation seeking in major depressive patients: Relationship to sub-threshold bipolarity and cyclothymic temperament
- Author
-
Fornaro, Michele, Ventriglio, Antonio, De Pasquale, Concetta, Pistorio, Maria Luisa, De Berardis, Domenico, Cattaneo, Carlo Ignazio, Favaretto, Ettore, Martinotti, Giovanni, Tomasetti, Carmine, Elassy, Mai, D'Angelo, Emanuela, Mungo, Sergio, Del Debbio, Alessandro, Romano, Anna, Ciampa, Giovanni, and Colicchio, Salvatore
- Published
- 2013
- Full Text
- View/download PDF
3. An integrated video-analysis software system designed for movement detection and sleep analysis. Validation of a tool for the behavioural study of sleep
- Author
-
Scatena, Michele, Dittoni, Serena, Maviglia, Riccardo, Frusciante, Roberto, Testani, Elisa, Vollono, Catello, Losurdo, Anna, Colicchio, Salvatore, Gnoni, Valentina, Labriola, Claudio, Farina, Benedetto, Pennisi, Mariano Alberto, and Della Marca, Giacomo
- Published
- 2012
- Full Text
- View/download PDF
4. Electroretinographic assessment in major depressed patients receiving duloxetine: Might differences between responders and non-responders indicate a differential biological background?
- Author
-
Fornaro, Michele, Bandini, Fabio, Ogliastro, Carla, Cordano, Christian, Martino, Matteo, Cestari, Luca, Escelsior, Andrea, Rocchi, Giulio, Colicchio, Salvatore, and Perugi, Giulio
- Published
- 2011
- Full Text
- View/download PDF
5. Pycnodysostosis with extreme sleep apnea: a possible alternative to tracheotomy
- Author
-
Della Marca, Giacomo, Scarano, Emanuele, Leoni, Chiara, Dittoni, Serena, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Vollono, Catello, and Zampino, Giuseppe
- Published
- 2012
- Full Text
- View/download PDF
6. Cephalometric findings in facioscapulohumeral muscular dystrophy patients with obstructive sleep apneas
- Author
-
Della Marca, Giacomo, Pantanali, Francesca, Frusciante, Roberto, Scarano, Emanuele, Cianfoni, Alessandro, Calò, Lea, Dittoni, Serena, Vollono, Catello, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Iannaccone, Elisabetta, Farina, Benedetto, Pirronti, Tommaso, Tonali, Pietro A., and Ricci, Enzo
- Published
- 2011
- Full Text
- View/download PDF
7. Upper airway surgery of obstructive sleep apnea in pycnodysostosis: Case report and literature review
- Author
-
Testani, Elisa, Scarano, Emanuele, Leoni, Chiara, Dittoni, Serena, Losurdo, Anna, Colicchio, Salvatore, Gnoni, Valentina, Vollono, Catello, Zampino, Giuseppe, Paludetti, Gaetano, and Marca, Giacomo Della
- Published
- 2014
- Full Text
- View/download PDF
8. Pain and the Alpha-Sleep Anomaly: A Mechanism of Sleep Disruption in Facioscapulohumeral Muscular Dystrophy
- Author
-
Della Marca, Giacomo, Frusciante, Roberto, Vollono, Catello, Iannaccone, Elisabetta, Dittoni, Serena, Losurdo, Anna, Testani, Elisa, Gnoni, Valentina, Colicchio, Salvatore, Di Blasi, Chiara, Erra, Carmen, Mazza, Salvatore, and Ricci, Enzo
- Published
- 2013
- Full Text
- View/download PDF
9. Oculogyric Crisis in a Midbrain Lesion
- Author
-
Della Marca, Giacomo, Frisullo, Giovanni, Vollono, Catello, Dittoni, Serena, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Rizzo, Daniela, Riccardi, Riccardo, and Batocchi, Anna Paola
- Published
- 2011
- Full Text
- View/download PDF
10. Abnormal Sexual Behavior During Sleep
- Author
-
Marca, Giacomo Della, Dittoni, Serena, Frusciante, Roberto, Colicchio, Salvatore, Losurdo, Anna, Testani, Elisa, Buccarella, Cristina, Modoni, Anna, Mazza, Salvatore, Mennuni, Gioacchino Francesco, Mariotti, Paolo, and Vollono, Catello
- Published
- 2009
- Full Text
- View/download PDF
11. An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects
- Author
-
Benvenuti Marzia, Colicchio Salvatore, Dalmasso Bruna, Martino Matteo, Fornaro Michele, Rocchi Giulio, Escelsior Andrea, and Perugi Giulio
- Subjects
Psychiatry ,RC435-571 - Abstract
Abstract Background Despite multiple antidepressant options, major depressive disorder (MDD) still faces high non-response rates, eventually requiring anticonvulsant augmentation strategies too. The aim of this study was to explore such a potential role for zonisamide. Methods A total of 40 MDD outpatients diagnosed using the Diagnostic and Statistical Manual for Mental Disorders, fourth edition criteria entered a 24 week open trial receiving duloxetine 60 mg/day for the first 12 weeks and subsequently (weeks 12 to 24) augmentation with zonisamide 75 mg/day if they did not respond to the initial monotherapy. Efficacy and tolerability were assessed using the Hamilton Scales for Anxiety and Depression (a 12 week score ≥50% vs baseline defined 'non-response'), the Arizona Sexual Experience Scale, the Patient Rated Inventory of Side Effects and the Young Mania Rating Scale. Results At week 12, 15 patients out of 39 (38.5%) were responders, and 1 had dropped out; remarkably, 14 patients out of 24 (58.3%) had achieved response by week 24. Poor concentration and general malaise were associated with non-response both at week 12 and 24 (P = 0.001), while loss of libido and reduced energy were prominent among final timepoint non-responders. Patients receiving zonisamide also experienced weight reduction (2.09 ± 12.14 kg; P = 0.001) independently of the outcome. Conclusions Although only a preliminary study due to strong methodological limitations, and thus requiring confirmation by further controlled investigations, the current results indicate zonisamide may be a potential augmentation option for some depressed patients receiving low doses of duloxetine.
- Published
- 2011
- Full Text
- View/download PDF
12. Sleep-related modification of atrioventricular block: from first-degree to second-degree, Mobitz type II
- Author
-
Colicchio, Salvatore, Della Marca, Giacomo, Vollono, Catello, Quatrale, Marianna, and Janiri, Luigi
- Published
- 2015
- Full Text
- View/download PDF
13. NGF serum levels variations in major depressed patients receiving duloxetine
- Author
-
Martino, Matteo, Rocchi, Giulio, Escelsior, Andrea, Contini, Paola, Colicchio, Salvatore, de Berardis, Domenico, Amore, Mario, Fornaro, Pantaleo, and Fornaro, Michele
- Published
- 2013
- Full Text
- View/download PDF
14. Clinical insights by the presence of bipolar disorder in pseudohypoparathyroidism type 1A
- Author
-
Kadilli, Irket, Colicchio, Salvatore, Guglielmo, Riccardo, Vollono, Catello, Della Marca, Giacomo, Janiri, Luigi, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Janiri, Luigi (ORCID:0000-0002-1633-9418), Kadilli, Irket, Colicchio, Salvatore, Guglielmo, Riccardo, Vollono, Catello, Della Marca, Giacomo, Janiri, Luigi, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), and Janiri, Luigi (ORCID:0000-0002-1633-9418)
- Abstract
Pseudohypoparathyroidism type 1A and its association with bipolar disorder (BD) have never been reported so far. We report a new case with both clinical entities and discuss the potential pathophysiological mechanisms of this association (protein kinase A hypoactivation, parathyroid hormone, hypocalcemia, protein kinase C activation, vitamin D deficiency). In this patient, the correction of the underlying calcium and vitamin D deficiencies leads to a better BD outcome and lower dosage of psychopharmacological agents. The conclusions might be generalized for a better understanding and management of these conditions
- Published
- 2015
15. Clinical insights by the presence of bipolar disorder in pseudohypoparathyroidism type 1A
- Author
-
Kadilli, Irket, primary, Colicchio, Salvatore, additional, Guglielmo, Riccardo, additional, Vollono, Catello, additional, Marca, Giacomo della, additional, and Janiri, Luigi, additional
- Published
- 2015
- Full Text
- View/download PDF
16. A Case of Treatment Resistant Depression and Alcohol Abuse in a Person with Mental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple Antidepressant Trials
- Author
-
Fornaro, Michele, Ciampa, Giovanni, Mosti, Nicola, Del Carlo, Alessandra, Ceraudo, Giuseppe, and Colicchio, Salvatore
- Subjects
Article Subject - Abstract
Mental Retardation (MR) is a developmental disability characterized by impairments in adaptive daily life skills and difficulties in social and interpersonal functioning. Since multiple causes may contribute to MR, associated clinical pictures may vary accordingly. Nevertheless, when psychiatric disorders as Treatment Resistant Depression (TRD) and/or alcohol abuse co-exist, their proper detection and management is often troublesome, essentially due to a limited vocabulary MR people could use to describe their symptoms, feelings and concerns, and the lack of reliable screening tools. Furthermore, MR people are among the most medicated subjects, with (over) prescription of antidepressants and/or typical antipsychotics being the rule rather than exception. Thus, treatment resistance or even worsening of depression, constitute frequent occurrences. This report describes the case of a person with MR who failed to respond to repetitive trials of antidepressant monotherapies, finally recovering using aripiprazole to fluvoxamine augmentation upon consideration of a putative bipolar diathesis for “agitated” TRD. Although further controlled investigations are needed to assess a putative bipolar diathesis in some cases of MR associated to TRD, prudence is advised in the long-term prescription of antidepressant monotherapies in such conditions.
- Published
- 2010
- Full Text
- View/download PDF
17. Heart rate and heart rate variability modification in chronic insomnia patients
- Author
-
Farina, B, Dittoni, Serena, Colicchio, Salvatore, Testani, Elisa, Losurdo, Anna, Gnoni, Valentina, Di Blasi, Chiara, Brunetti, R, Contardi, A, Mazza, Salvatore, Della Marca, Giacomo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Farina, B, Dittoni, Serena, Colicchio, Salvatore, Testani, Elisa, Losurdo, Anna, Gnoni, Valentina, Di Blasi, Chiara, Brunetti, R, Contardi, A, Mazza, Salvatore, Della Marca, Giacomo, and Della Marca, Giacomo (ORCID:0000-0001-6914-799X)
- Abstract
Chronic insomnia is highly prevalent in the general population, provoking personal distress and increased risk for psychiatric and medical disorders. Autonomic hyper-arousal could be a pathogenic mechanism of chronic primary insomnia. The aim of this study was to investigate autonomic activity in patients with chronic primary insomnia by means of heart rate variability (HRV) analysis. Eighty-five consecutive patients affected by chronic primary insomnia were enrolled (38 men and 47 women; mean age: 53.2 ± 13.6). Patients were compared with a control group composed of 55 healthy participants matched for age and gender (23 men and 32 women; mean age: 54.2 ± 13.9). Patients underwent an insomnia study protocol that included subjective sleep evaluation, psychometric measures, and home-based polysomnography with evaluation of HRV in wake before sleep, in all sleep stages, and in wake after final awakening. Patients showed modifications of heart rate and HRV parameters, consistent with increased sympathetic activity, while awake before sleep and during Stage-2 non-REM sleep. No significant differences between insomniacs and controls could be detected during slow-wave sleep, REM sleep, and post-sleep wake. These results are consistent with the hypothesis that autonomic hyper-arousal is a major pathogenic mechanism in primary insomnia, and confirm that this condition is associated with an increased cardiovascular risk.
- Published
- 2014
18. Heart Rate and Heart Rate Variability Modification in Chronic Insomnia Patients
- Author
-
Farina, Benedetto, Dittoni, Serena, Colicchio, Salvatore, Testani, Elisa, Losurdo, Anna, Gnoni, Valentina, Di Blasi, Chiara, Brunetti, Riccardo, Contardi, Anna, Mazza, Salvatore, Della Marca, Giacomo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Farina, Benedetto, Dittoni, Serena, Colicchio, Salvatore, Testani, Elisa, Losurdo, Anna, Gnoni, Valentina, Di Blasi, Chiara, Brunetti, Riccardo, Contardi, Anna, Mazza, Salvatore, Della Marca, Giacomo, and Della Marca, Giacomo (ORCID:0000-0001-6914-799X)
- Abstract
Chronic insomnia is highly prevalent in the general population, provoking personal distress and increased risk for psychiatric and medical disorders. Autonomic hyper-arousal could be a pathogenic mechanismof chronic primary insomnia. The aim of this study was to investigate autonomic activity in patients with chronic primary insomnia by means of heart rate variability (HRV) analysis. Eighty-five consecutive patients affected by chronic primary insomnia were enrolled (38 men and 47 women; mean age: 53.2 ̇ 13.6). Patients were compared with a control group composed of 55 healthy participants matched for age and gender (23 men and 32 women; mean age: 54.2 ̇ 13.9). Patients underwent an insomnia study protocol that included subjective sleep evaluation, psychometric measures, and home-based polysomnography with evaluation of HRV in wake before sleep, in all sleep stages, and in wake after final awakening. Patients showed modifications of heart rate and HRV parameters, consistent with increased sympathetic activity, while awake before sleep and during Stage-2 non-REM sleep. No significant differences between insomniacs and controls could be detected during slow-wave sleep, REM sleep, and post-sleep wake. These results are consistent with the hypothesis that autonomic hyper-arousal is a major pathogenic mechanism in primary insomnia, and confirm that this condition is associated with an increased cardiovascular risk.
- Published
- 2014
19. Bilateral thalamic stroke transiently reduces arousals and NREM sleep instability
- Author
-
Luigetti, Marco, Di Lazzaro, Vincenzo, Broccolini, Aldobrando, Vollono, Catello, Dittoni, Serena, Frisullo, Giovanni, Pilato, Fabio, Profice, Paolo, Losurdo, Anna, Morosetti, Roberta, Testani, Elisa, Colicchio, Salvatore, and Marca, Giacomo Della
- Published
- 2011
- Full Text
- View/download PDF
20. Heart Rate Variability in Sleep-Related Migraine without Aura
- Author
-
Vollono, Catello, Gnoni, Valentina, Dittoni, Serena, Losurdo, Anna, Colicchio, Salvatore, Testani, Elisa, Di Blasi, Chiara, Mazza, Salvatore, Farina, Benedetto, Della Marca, Giacomo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Vollono, Catello, Gnoni, Valentina, Dittoni, Serena, Losurdo, Anna, Colicchio, Salvatore, Testani, Elisa, Di Blasi, Chiara, Mazza, Salvatore, Farina, Benedetto, Della Marca, Giacomo, and Della Marca, Giacomo (ORCID:0000-0001-6914-799X)
- Abstract
Objectives: This is an observational study aimed to investigate the activity of autonomic nervous system during sleep in patients with sleep-related migraine. Methods: Eight consecutive migraineurs without aura were enrolled (6 women and 2 men), aged 30 to 62 years (mean 48.1 ± 9.3 years). Inclusion criteria were: high frequency of attacks (> 5 per month) and occurrence of more than 75% of the attacks during sleep causing an awakening. Patients were compared with a control group of 55 healthy subjects (23 men and 32 women, mean age 54.2 ± 13.0 years), and with a further control group of 8 age- and gender-matched healthy controls. Patient and controls underwent polysomnography and heart rate variability analysis. Results: A signifi cant reduction of the LF/HF ratio during N2 and N3 sleep stages was observed in migraineurs compared with controls. No differences in sleep macrostructure were observed; CAP time and CAP rate were lower in migraineurs than in controls. Conclusions: These fi ndings indicate a peculiar modifi cation of the autonomic balance during sleep in sleep-related migraine. The reduction of LF/HF ratio in NREM sleep was observed in controls, but it was quantitatively much more evident in migraineurs. Changes in LF/HF could be consequent to an autonomic unbalance which could manifest selectively (or alternatively become more evident) during sleep. These fi ndings, together with the reduction in CAP rate, could be an expression of reduced arousability during sleep in patients with sleep-related migraine. The simultaneous involvement of the autonomic, arousal, and pain systems might suggest involvement of the hypothalamic pathways.
- Published
- 2013
21. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
- Author
-
Fornaro,Michele, McCarthy,Michael J, De Berardis,Domenico, De Pasquale,Concetta, Tabaton,Massimo, Martino,Matteo, Colicchio,Salvatore, Cattaneo,Carlo Ignazio, D'Angelo,Emanuela, Fornaro,Pantaleo, Fornaro,Michele, McCarthy,Michael J, De Berardis,Domenico, De Pasquale,Concetta, Tabaton,Massimo, Martino,Matteo, Colicchio,Salvatore, Cattaneo,Carlo Ignazio, D'Angelo,Emanuela, and Fornaro,Pantaleo
- Abstract
Michele Fornaro,1 Michael J McCarthy,2,3 Domenico De Berardis,4 Concetta De Pasquale,1 Massimo Tabaton,5 Matteo Martino,6 Salvatore Colicchio,7 Carlo Ignazio Cattaneo,8 Emanuela D'Angelo,9 Pantaleo Fornaro61Department of Formative Sciences, University of Catania, Catania, Italy; 2Department of Psychiatry, Veteran's Affairs San Diego Healthcare System, 3University of California San Diego, La Jolla, CA, USA; 4Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, "ASL 4", Teramo, Italy; 5Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy; 6Department of Neurosciences, Section of Psychiatry, University of Genova, Genoa, Italy; 7Unit of Sleep Medicine, Department of Neuroscience, Catholic University, Rome, Italy; 8National Health System, "ASL 13", Novara, Italy; 9National Health System, "ASL 3", Genoa, ItalyPurpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression.Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale–Bipolar Version, Young Mania Rating Scale, and body mass index.Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the first endp
- Published
- 2013
22. An integrated video-analysis software system designed for movement detection and sleep analysis. Validation of a tool for the behavioural study of sleep
- Author
-
Scatena, M, Dittoni, Serena, Maviglia, Riccardo, Frusciante, Roberto, Testani, Elisa, Vollono, Catello, Losurdo, Anna, Colicchio, Salvatore, Gnoni, Valentina, Labriola, C, Farina, B, Pennisi, Mariano, Della Marca, Giacomo, Pennisi, Mariano (ORCID:0000-0001-8761-5144), Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Scatena, M, Dittoni, Serena, Maviglia, Riccardo, Frusciante, Roberto, Testani, Elisa, Vollono, Catello, Losurdo, Anna, Colicchio, Salvatore, Gnoni, Valentina, Labriola, C, Farina, B, Pennisi, Mariano, Della Marca, Giacomo, Pennisi, Mariano (ORCID:0000-0001-8761-5144), and Della Marca, Giacomo (ORCID:0000-0001-6914-799X)
- Abstract
The aim of the present study was to develop and validate a software tool for the detection of movements during sleep, based on the automated analysis of video recordings. This software is aimed to detect and quantify movements and to evaluate periods of sleep and wake.
- Published
- 2012
23. Increased sleep spindle activity in patients with Costello syndrome (HRAS gene mutation)
- Author
-
Della Marca, Giacomo, Leoni, Chiara, Dittoni, Serena, Battaglia, Domenica Immacolata, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Gambardella, Ml, Mariotti, Paolo, Alfieri, Paolo, Tartaglia, Marco, Zampino, Giuseppe, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Battaglia, Domenica Immacolata (ORCID:0000-0003-0491-4021), Zampino, Giuseppe (ORCID:0000-0003-3865-3253), Della Marca, Giacomo, Leoni, Chiara, Dittoni, Serena, Battaglia, Domenica Immacolata, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Gambardella, Ml, Mariotti, Paolo, Alfieri, Paolo, Tartaglia, Marco, Zampino, Giuseppe, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Battaglia, Domenica Immacolata (ORCID:0000-0003-0491-4021), and Zampino, Giuseppe (ORCID:0000-0003-3865-3253)
- Abstract
Costello syndrome is a congenital disorder because of HRAS gene mutation, frequently associated with neurologic impairment and sleep disorders. The aims of the study were to evaluate the sleep EEG, and particularly the sleep spindles, in a population of patients with Costello syndrome and to compare them with those characterizing unaffected subjects. Eleven subjects (5 men and 6 women) with Costello syndrome were included in the study; age ranged between 18 months and 31 years (mean, 9.6 ± 9.4 years). The diagnosis was posed on the basis of established clinical criteria and confirmed molecularly. Sleep EEG was studied by means of full-night, laboratory-based video-polysomnography, performed overnight, during hospitalization. Sleep activity was quantified by means of power spectral analysis. Patients heterozygous for an HRAS mutation exhibited increased EEG power in 12- to 15-Hz activity band compared with age-matched control subjects. In conclusion, the authors observed a consistent increase in the amplitude of cortical sleep spindles in all our subjects with an HRAS mutation. These "giant" spindles were not associated with any evidence of structural damage of the cortex or the thalami and should be considered as phenotypic feature of sleep EEG activity in Costello syndrome because of HRAS mutation.
- Published
- 2011
24. Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
- Author
-
Fornaro,Michele, Martino,Matteo, Battaglia,Florinda, Colicchio,Salvatore, Perugi,Giulio, Fornaro,Michele, Martino,Matteo, Battaglia,Florinda, Colicchio,Salvatore, and Perugi,Giulio
- Abstract
Michele Fornaro1, Matteo Martino1, Florinda Battaglia2, Salvatore Colicchio3, Giulio Perugi41Department of Neuroscience, Section of Psychiatry, University of Genova, Genoa, Italy; 2Center of Excellence for Biomedical Research (CEBR), Genoa, Italy; 3Department of Neurosciences, Catholic University, Rome, Italy; 4Department of Psychiatry, Institute of Behavioral Sciences, University of Pisa, Pisa, ItalyBackground: Immune modifications, including changes in interleukin (IL)-6 levels, have often been observed in major depressive disorder (MDD) during treatment with selective serotonin reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine. Nevertheless, no equivalent observation for the SNRI duloxetine has been made to date.Method: Sixteen patients diagnosed with MDD and an actual major depressive episode according to DSM-IV criteria and 16 healthy controls entered a 6-week trial with duloxetine 60 mg/day. All subjects (n = 32) were assessed using the Hamilton Depression Rating Scale (HAM-D), the Young Mania Rating Scale (YMRS), and were monitored for IL-6 levels both at baseline and at week 6. Blood samples for IL-6 levels were evaluated by ELISA.Results: After 6 weeks of treatment, the mean total scores for HAM-D declined both in the depressed and control groups, while IL-6 modification showed an opposite trend both in depressed (12.38 ± 19.80 to 19.73 ± 18.94 pg/mL) and control subjects (12.25 ± 21.12 to 17.63 ± 20.44 pg/mL), as did YMRS (ns), although none of the subjects switched to (hypo)mania. Of note, IL-6 levels increased significantly only in the responders subgroup (n = 9; P = 0.012).Conclusion: The small sample size and weak design of this study limit the validity of our results, which should be regarded as preliminary only. Nonetheless, the trend of increasing IL-6 levels observed in responder patients treated with duloxetine should prompt further controlled, extended stu
- Published
- 2011
25. Decreased nocturnal movements in patients with facioscapulohumeral muscular dystrophy
- Author
-
Della Marca, Giacomo, Frusciante, Roberto, Dittoni, Serena, Vollono, Catello, Losurdo, Anna, Testani, Elisa, Scarano, Emanuele, Colicchio, Salvatore, Iannaccone, Elisabetta, Tonali, Pietro Attilio, Ricci, Enzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Scarano, Emanuele (ORCID:0000-0003-2570-1121), Ricci, Enzo (ORCID:0000-0003-3092-3597), Della Marca, Giacomo, Frusciante, Roberto, Dittoni, Serena, Vollono, Catello, Losurdo, Anna, Testani, Elisa, Scarano, Emanuele, Colicchio, Salvatore, Iannaccone, Elisabetta, Tonali, Pietro Attilio, Ricci, Enzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Scarano, Emanuele (ORCID:0000-0003-2570-1121), and Ricci, Enzo (ORCID:0000-0003-3092-3597)
- Abstract
Reduced mobility during sleep characterizes a variety of movement disorders and neuromuscular diseases. Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of muscular dystrophy in the general population, and people with FSHD have poor sleep quality. The aims of the present study were to evaluate nocturnal motor activity in patients with FSHD by means of videopolysomnography and to verify whether activity was associated with modifications in sleep structure.
- Published
- 2010
26. Teaching NeuroImages: transient epileptic amnesia.
- Author
-
Della Marca, Giacomo, Dittoni, Serena, Pilato, Fabio, Profice, Paolo, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Colosimo, Cesare, Di Lazzaro, Vincenzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Pilato, Fabio (ORCID:0000-0002-7248-3916), Colosimo, Cesare (ORCID:0000-0003-3800-3648), Della Marca, Giacomo, Dittoni, Serena, Pilato, Fabio, Profice, Paolo, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Colosimo, Cesare, Di Lazzaro, Vincenzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Pilato, Fabio (ORCID:0000-0002-7248-3916), and Colosimo, Cesare (ORCID:0000-0003-3800-3648)
- Published
- 2010
27. The stolen memory: a case of transient global amnesia
- Author
-
Della Marca, Giacomo, Broccolini, Aldobrando, Vollono, Catello, Dittoni, Serena, Frisullo, Giovanni, Pilato, Fabio, Profice, Paolo, Morosetti, Roberta, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Di Lazzaro, Vincenzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Broccolini, Aldobrando (ORCID:0000-0001-8295-9271), Pilato, Fabio (ORCID:0000-0002-7248-3916), Della Marca, Giacomo, Broccolini, Aldobrando, Vollono, Catello, Dittoni, Serena, Frisullo, Giovanni, Pilato, Fabio, Profice, Paolo, Morosetti, Roberta, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Di Lazzaro, Vincenzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Broccolini, Aldobrando (ORCID:0000-0001-8295-9271), and Pilato, Fabio (ORCID:0000-0002-7248-3916)
- Abstract
Transient global amnesia (TGA) is a clinical syndrome characterized by the abrupt onset of anterograde amnesia without other neurological deficits. The ability to lay down new memories recovers gradually, in minutes to hours, with an average of 4 to 6 hours (1), leaving only a dense amnesic gap for the duration of the episode. Transient global amnesia is likely to be due to an acute impairment of the hippocampus (2) but the etiopathogenesis is debated. Ischemia, epileptiform activity, and psychological factors may contribute to TGA. The strongest argument in favor of the ischemic etiology is the presence of a small area of restricted diffusion-weighted imaging (DWI) signal in the hippocampus, which appears in the magnetic resonance imaging (MRI) scan data of most patients with TGA (1 and 3). Diffusion-weighted imaging hypersignal indicates cytotoxic edema; therefore, it is considered the hallmark of brain ischemia (4). Nevertheless, an analysis of risk factors leads to the conclusion that the cerebrovascular etiology is unlikely, even in individuals with DWI lesions (5). An epileptic origin has been considered (6) but it appears unlikely, because of the long duration and the low recurrence rate of the episodes and the absence of convulsions, impairment of consciousness, or other signs of cortical dysfunction (7). Finally, psychogenic origin has been proposed: TGA commonly occurs in periods of stress, overwork, and emotional arousal (7) or after stressful events, pain, or sexual intercourse. As follows, we describe a patient with TGA in whom the clinical, neuroimaging, and electroencephalogram (EEG) findings demonstrate a transient, reversible, dysfunction of the hippocampus.
- Published
- 2010
28. Heart rate variability in facioscapulohumeral muscular dystrophy.
- Author
-
Della Marca, Giacomo, Frusciante, Roberto, Scatena, Michele, Dittoni, Serena, Testani, Elisa, Vollono, Catello, Losurdo, Anna, Scarano, Emanuele, Colicchio, Salvatore, Farina, Benedetto, Gnoni, Valentina, Mazza, Salvatore, Tonali, Pietro Attilio, Ricci, Enzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Scarano, Emanuele (ORCID:0000-0003-2570-1121), Ricci, Enzo (ORCID:0000-0003-3092-3597), Della Marca, Giacomo, Frusciante, Roberto, Scatena, Michele, Dittoni, Serena, Testani, Elisa, Vollono, Catello, Losurdo, Anna, Scarano, Emanuele, Colicchio, Salvatore, Farina, Benedetto, Gnoni, Valentina, Mazza, Salvatore, Tonali, Pietro Attilio, Ricci, Enzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Scarano, Emanuele (ORCID:0000-0003-2570-1121), and Ricci, Enzo (ORCID:0000-0003-3092-3597)
- Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is the third most frequent form of muscular dystrophy. Heart rate variability (HRV) analysis is a means of evaluating the activity of the autonomic nervous system. The aim of this study was to evaluate HRV in FSHD patients. Fifty-five consecutive FSHD patients were enrolled (31 men, age 26-72 years). Muscular impairment was measured using a clinical severity scale (CSS). Patients were compared with a control group of 55 healthy subjects, matched for age and sex. HRV was analyzed in the time domain and in the frequency domain. Patients showed increased spectral power of the low-frequency band. Spectral power of the high-frequency band was inversely correlated with CSS score. FSHD is associated with a slight increase in sympathetic output and with a decrease in parasympathetic output. These modifications become more evident with the progression of the disease and could increase the risk of arrhythmias and other cardiovascular events
- Published
- 2010
29. The stolen memory. A case of Transient Global Amnesia.
- Author
-
Della Marca, Giacomo, Broccolini, Aldobrando, Vollono, Catello, Dittoni, Serena, Frisullo, Giovanni, Pilato, Fabio, Profice, Paolo, Morosetti, Roberta, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Di Lazzaro, Vincenzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Broccolini, Aldobrando (ORCID:0000-0001-8295-9271), Pilato, Fabio (ORCID:0000-0002-7248-3916), Della Marca, Giacomo, Broccolini, Aldobrando, Vollono, Catello, Dittoni, Serena, Frisullo, Giovanni, Pilato, Fabio, Profice, Paolo, Morosetti, Roberta, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Di Lazzaro, Vincenzo, Della Marca, Giacomo (ORCID:0000-0001-6914-799X), Broccolini, Aldobrando (ORCID:0000-0001-8295-9271), and Pilato, Fabio (ORCID:0000-0002-7248-3916)
- Published
- 2009
30. Heart Rate and Heart Rate Variability Modification in Chronic Insomnia Patients
- Author
-
Farina, Benedetto, primary, Dittoni, Serena, additional, Colicchio, Salvatore, additional, Testani, Elisa, additional, Losurdo, Anna, additional, Gnoni, Valentina, additional, Di Blasi, Chiara, additional, Brunetti, Riccardo, additional, Contardi, Anna, additional, Mazza, Salvatore, additional, and Della Marca, Giacomo, additional
- Published
- 2013
- Full Text
- View/download PDF
31. Heart Rate Variability in Sleep-Related Migraine without Aura
- Author
-
Vollono, Catello, primary, Gnoni, Valentina, additional, Testani, Elisa, additional, Dittoni, Serena, additional, Losurdo, Anna, additional, Colicchio, Salvatore, additional, Di Blasi, Chiara, additional, Mazza, Salvatore, additional, Farina, Benedetto, additional, and Della Marca, Giacomo, additional
- Published
- 2013
- Full Text
- View/download PDF
32. A case of severe oral self-injurious Tourette's syndrome alleviated by pregabalin
- Author
-
Fornaro, Michele, primary, Maremmani, Angelo Giovanni Icro, additional, Colicchio, Maria Giovanna, additional, Romano, Anna, additional, Fornaro, Stefania, additional, Rizzato, Salvatore, additional, Ciampa, Giovanni, additional, Colicchio, Salvatore, additional, and Dell'Osso, Liliana, additional
- Published
- 2012
- Full Text
- View/download PDF
33. An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects
- Author
-
Fornaro, Michele, primary, Martino, Matteo, additional, Dalmasso, Bruna, additional, Colicchio, Salvatore, additional, Benvenuti, Marzia, additional, Rocchi, Giulio, additional, Escelsior, Andrea, additional, and Perugi, Giulio, additional
- Published
- 2011
- Full Text
- View/download PDF
34. Increased Sleep Spindle Activity in Patients With Costello Syndrome (HRAS Gene Mutation)
- Author
-
Marca, Giacomo Della, primary, Leoni, Chiara, additional, Dittoni, Serena, additional, Battaglia, Domenica, additional, Losurdo, Anna, additional, Testani, Elisa, additional, Colicchio, Salvatore, additional, Gnoni, Valentina, additional, Gambardella, Maria L., additional, Mariotti, Paolo, additional, Alfieri, Paolo, additional, Tartaglia, Marco, additional, and Zampino, Giuseppe, additional
- Published
- 2011
- Full Text
- View/download PDF
35. Pycnodysostosis with extreme sleep apnea: a possible alternative to tracheotomy
- Author
-
Della Marca, Giacomo, primary, Scarano, Emanuele, additional, Leoni, Chiara, additional, Dittoni, Serena, additional, Losurdo, Anna, additional, Testani, Elisa, additional, Colicchio, Salvatore, additional, Gnoni, Valentina, additional, Vollono, Catello, additional, and Zampino, Giuseppe, additional
- Published
- 2011
- Full Text
- View/download PDF
36. Improvement of obstructive sleep apneas caused by hydrocephalus associated with Chiari malformation Type II following surgery
- Author
-
Luigetti, Marco, primary, Losurdo, Anna, additional, Dittoni, Serena, additional, Testani, Elisa, additional, Colicchio, Salvatore, additional, Gnoni, Valentina, additional, Farina, Benedetto, additional, Scarano, Emanuele, additional, Zampino, Giuseppe, additional, Mariotti, Paolo, additional, Rendeli, Claudia, additional, Di Rocco, Concezio, additional, Massimi, Luca, additional, and Marca, Giacomo Della, additional
- Published
- 2010
- Full Text
- View/download PDF
37. A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
- Author
-
Fornaro, Michele, primary, Prestia, Davide, additional, Colicchio, Salvatore, additional, and Perugi, Giulio, additional
- Published
- 2010
- Full Text
- View/download PDF
38. Decreased Nocturnal Movements in Patients with Facioscapulohumeral Muscular Dystrophy
- Author
-
Marca, Giacomo Della, primary, Frusciante, Roberto, additional, Dittoni, Serena, additional, Vollono, Catello, additional, Losurdo, Anna, additional, Testani, Elisa, additional, Scarano, Emanuele, additional, Colicchio, Salvatore, additional, Iannaccone, Elisabetta, additional, Tonali, Pietro A., additional, and Ricci, Enzo, additional
- Published
- 2010
- Full Text
- View/download PDF
39. The Stolen Memory: A Case of Transient Global Amnesia
- Author
-
Della Marca, Giacomo, primary, Broccolini, Aldobrando, additional, Vollono, Catello, additional, Dittoni, Serena, additional, Frisullo, Giovanni, additional, Pilato, Fabio, additional, Profice, Paolo, additional, Morosetti, Roberta, additional, Losurdo, Anna, additional, Testani, Elisa, additional, Colicchio, Salvatore, additional, and Di Lazzaro, Vincenzo, additional
- Published
- 2010
- Full Text
- View/download PDF
40. Cephalometric findings in facioscapulohumeral muscular dystrophy patients with obstructive sleep apneas
- Author
-
Della Marca, Giacomo, primary, Pantanali, Francesca, additional, Frusciante, Roberto, additional, Scarano, Emanuele, additional, Cianfoni, Alessandro, additional, Calò, Lea, additional, Dittoni, Serena, additional, Vollono, Catello, additional, Losurdo, Anna, additional, Testani, Elisa, additional, Colicchio, Salvatore, additional, Gnoni, Valentina, additional, Iannaccone, Elisabetta, additional, Farina, Benedetto, additional, Pirronti, Tommaso, additional, Tonali, Pietro A., additional, and Ricci, Enzo, additional
- Published
- 2010
- Full Text
- View/download PDF
41. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study.
- Author
-
Fornaro, Michele, McCarthy, Michael J., De Berardis, Domenico, De Pasquale, Concetta, Tabaton, Massimo, Martino, Matteo, Colicchio, Salvatore, Ignazio Cattaneo, Carlo, D'Angelo, Emanuela, and Fornaro, Pantaleo
- Subjects
CIRCADIAN rhythms ,BIPOLAR disorder ,MENTAL depression ,THERAPEUTICS ,AFFECTIVE disorders ,DEPRESSED persons ,HYPOMANIA ,PATIENTS - Abstract
Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression. Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale-Bipolar Version, Young Mania Rating Scale, and body mass index. Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the first endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects responded. At 36 weeks, there was a slight yet statistically significant (P = 0.001) reduction in body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively. Week 36 drop outs were two hypomanic cases, one per group. Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/lithium for acute depression in BD-II, suggesting the need for confirmation by future double blind, controlled clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
42. Cephalometric findings in facioscapulohumeral muscular dystrophy patients with obstructive sleep apneas.
- Author
-
Marca, Giacomo Della, Pantanali, Francesca, Frusciante, Roberto, Scarano, Emanuele, Cianfoni, Alessandro, Calò, Lea, Dittoni, Serena, Vollono, Catello, Losurdo, Anna, Testani, Elisa, Colicchio, Salvatore, Gnoni, Valentina, Iannaccone, Elisabetta, Farina, Benedetto, Pirronti, Tommaso, Tonali, Pietro A., and Ricci, Enzo
- Abstract
Purposes: The purposes of the study are: (1) to establish if cephalometry and upper airway examination may provide tools for detecting facioscapulohumeral (FSHD) patients at risk for obstructive sleep apnea syndrome (OSAS); and (2) to correlate cephalometry and otorhinolaryngologic evaluation with clinical and polysomnographic features of FHSD patients with OSAS. Methods: Patients were 13 adults affected by genetically confirmed FSHD and OSAS, 11 men, with mean age 47.1 ± 12.8 years (range, 33-72 years). All underwent clinical evaluation, Manual Muscle Test, Clinical Severity Scale for FSHD, Epworth Sleepiness Scale, polysomnography, otorhinolaryngologic evaluation, and cephalometry. Results: Cephalometric evidence of pharyngeal narrowing [posterior airways space (PAS) < 10 mm] was present in only one patient. The mandibular planus and hyoid (MP-H) distance ranged from 6.5 to 33.1 mm (mean, 17.5 ± 7.8 mm). The mean length of soft palate (PNS-P) was 31.9 ± 4.8 mm (range, 22.2 to 39.7 mm). No patient presented an ANB angle > 7°. There was no significant correlation between cephalometric measures, clinical scores, and PSG indexes. PAS and MP-H were not related to the severity of the disease. Conclusions: Upper airway morphological evaluation is of poor utility in the clinical assessment of FSHD patients and do not allow to predict the occurrence of sleep-related upper airway obstruction. This suggests that the pathogenesis of OSAS in FSHD is dependent on the muscular impairment, rather than to the anatomy of upper airways. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
43. Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation.
- Author
-
Fornaro, Michele, Martino, Matteo, Battaglia, Florinda, Colicchio, Salvatore, and Perugi, Giulio
- Published
- 2011
- Full Text
- View/download PDF
44. Heart rate variability in facioscapulohumeral muscular dystrophy.
- Author
-
Marca, Giacomo Della, Frusciante, Roberto, Scatena, Michele, Dittoni, Serena, Testani, Elisa, Vollono, Catello, Losurdo, Anna, Scarano, Emanuele, Colicchio, Salvatore, Farina, Benedetto, Gnoni, Valentina, Mazza, Salvatore, Tonali, Pietro A., and Ricci, Enzo
- Published
- 2010
45. A Case of Treatment Resistant Depression and Alcohol Abuse in a Person withMental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple Antidepressant Trials
- Author
-
Fornaro, Michele, Ciampa, Giovanni, Mosti, Nicola, Del Carlo, Alessandra, Ceraudo, Giuseppe, and Colicchio, Salvatore
- Subjects
INTELLECTUAL disabilities ,DRUG resistance ,ALCOHOLISM ,MENTAL depression ,ANTIDEPRESSANTS ,DIATHESIS-stress model (Psychology) ,THERAPEUTICS - Abstract
Mental Retardation (MR) is a developmental disability characterized by impairments in adaptive daily life skills and difficulties in social and interpersonal functioning. Since multiple causes may contribute to MR, associated clinical pictures may vary accordingly.Nevertheless, when psychiatric disorders as Treatment ResistantDepression (TRD) and/or alcohol abuse co-exist, their proper detection and management is often troublesome, essentially due to a limited vocabulary MR people could use to describe their symptoms, feelings and concerns, and the lack of reliable screening tools. Furthermore, MR people are among the most medicated subjects, with (over) prescription of antidepressants and/or typical antipsychotics being the rule rather than exception. Thus, treatment resistance or even worsening of depression, constitute frequent occurrences. This report describes the case of a person with MR who failed to respond to repetitive trials of antidepressant monotherapies, finally recovering using aripiprazole to fluvoxamine augmentation upon consideration of a putative bipolar diathesis for "agitated" TRD. Although further controlled investigations are needed to assess a putative bipolar diathesis in some cases of MR associated to TRD, prudence is advised in the long-term prescription of antidepressant monotherapies in such conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
46. NGF serum levels variations in major depressed patients receiving duloxetine
- Author
-
Michele Fornaro, Mario Amore, Domenico De Berardis, Salvatore Colicchio, Paola Contini, Giulio Rocchi, Pantaleo Fornaro, Matteo Martino, Andrea Escelsior, Martino, Matteo, Rocchi, Giulio, Escelsior, Andrea, Contini, Paola, Colicchio, Salvatore, de Berardis, Domenico, Amore, Mario, Fornaro, Pantaleo, and Fornaro, Michele
- Subjects
Male ,Time Factors ,Endocrinology, Diabetes and Metabolism ,Drug Resistance ,Severity of Illness Index ,chemistry.chemical_compound ,Endocrinology ,Adaptation, Psychological ,Nerve Growth Factor ,Sympathomimetics ,Depression (differential diagnoses) ,NGF ,Neuronal Plasticity ,biology ,Depression ,Serotonin Uptake Inhibitor ,Middle Aged ,Pathophysiology ,Psychiatry and Mental health ,Treatment Outcome ,Duloxetine ,Major depressive disorder ,Antidepressant ,Female ,Psychology ,Neuro–endocrine–immune system ,Selective Serotonin Reuptake Inhibitors ,Human ,Neurotrophin ,Adult ,medicine.medical_specialty ,Sympathomimetic ,Time Factor ,Thiophenes ,Duloxetine Hydrochloride ,Thiophene ,Internal medicine ,Neuroplasticity ,medicine ,Humans ,Biological Psychiatry ,Depressive Disorder, Major ,Endocrine and Autonomic Systems ,Biomarker ,medicine.disease ,Nerve growth factor ,chemistry ,biology.protein ,Biomarkers ,Stress, Psychological - Abstract
Summary Backgrounds Nerve growth factor (NGF) is involved in the modulation of the neuro–endocrine–immune (NEI) system, whereas alterations in neuroplasticity and NEI homeostasis seem to play a role in the pathophysiology of major depressive disorder (MDD). Objective of the study was to investigate NGF levels variations in MDD patients during antidepressant treatment with duloxetine, a relatively newer SNRI. Methods 30 MDD patients and 32 healthy controls were assessed using Hamilton depression scale (HAM-D) and monitored for NGF serum levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. Results According to early clinical response to duloxetine (defined at week 6 by reduction >50% of baseline HAM-D score), MDD patients were distinguished in early responders (ER) and early non-responders (ENR), who overall reached clinical response at week 12. Laboratory analysis showed overall significant lower baseline NGF levels among depressed patients compared to healthy controls, not significantly in ER and significantly in ENR. During duloxetine treatment NGF levels further decreased in association with clinical response, reaching significantly lower values in ER at W6 compared to controls, and in ENR at W12 compared to baseline. Conclusions A decrease in NGF levels during duloxetine treatment in association to clinical response could be indicative of a relative restoring of NEI stress-adaptation system, since stressors, inducing neuronal instability due to neurotrophins activity changes, permits circuitry remodeling as background in the selection of alternative adaptive behaviors. However, the lower baseline NGF levels found in MDD patients that further decrease during the treatment could represent a lower neurotrophin set point, possibly reflecting a functional impairment in stress-adaptive neuroplasticity in depressive disorders.
- Published
- 2013
47. Sensation seeking in major depressive patients: Relationship to sub-threshold bipolarity and cyclothymic temperament
- Author
-
Carlo Ignazio Cattaneo, Anna Romano, Salvatore Colicchio, Carmine Tomasetti, Michele Fornaro, Alessandro Del Debbio, Sergio Mungo, Mai Elassy, Concetta De Pasquale, G. Ciampa, Maria Luisa Pistorio, Giovanni Martinotti, Antonio Ventriglio, Domenico De Berardis, Ettore Favaretto, Emanuela D'Angelo, Fornaro, Michele, Ventriglio, Antonio, De Pasquale, Concetta, Pistorio, Maria Luisa, De Berardis, Domenico, Cattaneo, Carlo Ignazio, Favaretto, Ettore, Martinotti, Giovanni, Tomasetti, Carmine, Elassy, Mai, D'Angelo, Emanuela, Mungo, Sergio, Del Debbio, Alessandro, Romano, Anna, Ciampa, Giovanni, and Colicchio, Salvatore
- Subjects
Male ,Bipolar Disorder ,HCL-32 ,Personality Inventory ,Comorbidity ,Surveys and Questionnaires ,Mass Screening ,Surveys and Questionnaire ,media_common ,Middle Aged ,Psychiatric Status Rating Scale ,Cyclothymic Disorder ,Diagnostic and Statistical Manual of Mental Disorder ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Clinical Psychology ,Anxiety ,Major depressive disorder ,Female ,medicine.symptom ,Case-Control Studie ,Psychology ,Human ,Clinical psychology ,Adult ,medicine.medical_specialty ,Adolescent ,media_common.quotation_subject ,Sensation ,Impulsivity ,behavioral disciplines and activities ,Young Adult ,mental disorders ,medicine ,Humans ,Sensation seeking ,Bipolar disorder ,Temperament ,Psychiatry ,Sensation seeking, cyclothymic temperament ,Bipolar disorder, HCL-32 ,Aged ,Psychiatric Status Rating Scales ,Depressive Disorder, Major ,medicine.disease ,Hypomania ,cyclothymic temperament ,Case-Control Studies - Abstract
Background High levels of sensation seeking (SS) have been traditionally reported for lifetime bipolar disorder (BD) and/or substance use disorder (SUD) rather than major depressive disorder (MDD). Nonetheless, a renewed clinical attention toward the burden of sub-threshold bipolarity in MDD, solicits for a better assessment of “unipolar” major depressive episodes (MDEs) via characterization of putative differential psychopathological patterns, including SS and predominant affective temperament. Methods Two hundred and eighty currently depressed cases of MDD and 87 healthy controls were screened using the Zuckerman's sensation seeking scale-Form-V, the Hypomania Check List-32-item (HCL-32), the Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire-110-item, the Barratt Impulsivity Scale-11-item, the State–Trait Anxiety Inventory modules and the Structured Clinical Interview for DSM-IV axis-I disorders. Cases were divided into HCL-32+(sub-threshold bipolar)/HCL-32−(“true” unipolar depressed) depending on the HCL-32 total score. Results Upon correlation and multivariate regression analyses, the HCL-32+ patients showed the highest levels of SS, higher prevalence of cyclothymic temperament, and higher rates of multiple lifetime axis-I co-morbidities, including SUD. Limits Recall bias on some diagnoses, including BD, grossly matched healthy control group, lack of ad-hoc validated measures for ADHD, SUD, or axis-II disorders. Conclusions In our sample, the occurrence of higher levels of SS in “sub-threshold” bipolar cases outlined a differential psychopathological profile compared to DSM-defined “true unipolar” cases of MDE. If confirmed by replication studies, these findings may aid clinicians in delivering a more accurate diagnosis and a safer use of antidepressants in some MDD cases.
- Published
- 2013
48. A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
- Author
-
Davide Prestia, Salvatore Colicchio, Michele Fornaro, Giulio Perugi, Fornaro, Michele, Prestia, Davide, Colicchio, Salvatore, and Perugi, Giulio
- Subjects
cognition ,medicine.medical_specialty ,genetic structures ,mood ,melatonin ,Article ,bipolar disorder ,Medicine ,Agomelatine ,Pharmacology (medical) ,Bipolar disorder ,Psychiatry ,Pharmacology ,business.industry ,General Medicine ,medicine.disease ,Melatonergic ,Psychiatry and Mental health ,Mood ,Neurology ,depression ,Alzheimer ,Antidepressant ,Neurology (clinical) ,business ,medicine.drug - Abstract
Objective: To present an updated, comprehensive review on clinical and pre-clinical studies on agomelatine. Method: A MEDLINE, Psycinfo and Web of Science search (1966-May 2009) was performed using the following keywords: agomelatine, melatonin, S20098, efficacy, safety, adverse effect, pharmacokinetic, pharmacodynamic, major depressive disorder, bipolar disorder, Seasonal Affective Disorder (SAD), Alzheimer, ADHD, Generalized Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), anxiety disorders and mood disorder. Study collection and data extraction: All articles in English identified by the data sources were evaluated. Randomized, controlled clinical trials involving humans were prioritized in the review. The physiological bases of melatonergic transmission were also examined to deepen the clinical comprehension of agomelatine’ melatonergic modulation. Data synthesis: Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C antagonist, has been reported to be an effective antidepressant therapy. Conclusions: Although a bias in properly assessing the “sleep core” of depression may still exist with current screening instruments, therefore making difficult to compare agomelatine’ efficacy to other antidepressant ones, comparative studies showed agomelatine to be an intriguing option for depression and, potentially, for other therapeutic targets as well.
- Published
- 2010
49. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
- Author
-
Carlo Ignazio Cattaneo, Pantaleo Fornaro, Domenico De Berardis, Michael McCarthy, Massimo Tabaton, Concetta De Pasquale, Michele Fornaro, Salvatore Colicchio, Emanuela D'Angelo, Matteo Martino, Fornaro, Michele, Mccarthy, Michael J, De Berardis, Domenico, De Pasquale, Concetta, Tabaton, Massimo, Martino, Matteo, Colicchio, Salvatore, Cattaneo, Carlo Ignazio, D'Angelo, Emanuela, and Fornaro, Pantaleo
- Subjects
Oncology ,medicine.medical_specialty ,Neuropsychiatric Disease and Treatment ,acute bipolar depression, adjunctive treatment, agomelatine bipolar disorder type-II ,Neurosciences. Biological psychiatry. Neuropsychiatry ,bipolar disorder type-II ,Melatonin ,Internal medicine ,mental disorders ,medicine ,Agomelatine ,Circadian rhythm ,Bipolar disorder ,RC346-429 ,Psychiatry ,Biological Psychiatry ,Original Research ,business.industry ,adjunctive treatment ,acute bipolar depression ,medicine.disease ,Melatonergic ,agomelatine bipolar disorder type-II ,Psychiatry and Mental health ,Mood ,Adjunctive treatment ,Antidepressant ,Neurology. Diseases of the nervous system ,sense organs ,business ,agomelatine ,RC321-571 ,medicine.drug - Abstract
Michele Fornaro,1 Michael J McCarthy,2,3 Domenico De Berardis,4 Concetta De Pasquale,1 Massimo Tabaton,5 Matteo Martino,6 Salvatore Colicchio,7 Carlo Ignazio Cattaneo,8 Emanuela D'Angelo,9 Pantaleo Fornaro61Department of Formative Sciences, University of Catania, Catania, Italy; 2Department of Psychiatry, Veteran's Affairs San Diego Healthcare System, 3University of California San Diego, La Jolla, CA, USA; 4Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, "ASL 4", Teramo, Italy; 5Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy; 6Department of Neurosciences, Section of Psychiatry, University of Genova, Genoa, Italy; 7Unit of Sleep Medicine, Department of Neuroscience, Catholic University, Rome, Italy; 8National Health System, "ASL 13", Novara, Italy; 9National Health System, "ASL 3", Genoa, ItalyPurpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression.Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale–Bipolar Version, Young Mania Rating Scale, and body mass index.Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the first endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects responded. At 36 weeks, there was a slight yet statistically significant (P = 0.001) reduction in body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively. Week 36 drop outs were two hypomanic cases, one per group.Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/lithium for acute depression in BD-II, suggesting the need for confirmation by future double blind, controlled clinical trials.Keywords: bipolar disorder type-II, acute bipolar depression, agomelatine, adjunctive treatment
- Published
- 2013
50. VEGF plasma level variations in duloxetine-treated patients with major depression
- Author
-
Giulio Rocchi, Pantaleo Fornaro, Matteo Martino, Andrea Escelsior, Salvatore Colicchio, Domenico De Berardis, Michele Fornaro, Massimo Ghio, Mario Amore, Paola Contini, Fornaro, Michele, Rocchi, Giulio, Escelsior, Andrea, Contini, Paola, Ghio, Massimo, Colicchio, Salvatore, De Berardis, Domenico, Amore, Mario, Fornaro, Pantaleo, and Martino, Matteo
- Subjects
Adult ,Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Angiogenesis ,Thiophenes ,Duloxetine Hydrochloride ,chemistry.chemical_compound ,Thiophene ,Internal medicine ,medicine ,Humans ,Duloxetine ,Depression (differential diagnoses) ,Depressive Disorder, Major ,Depression ,Neurogenesis ,Middle Aged ,medicine.disease ,VEGF ,Antidepressive Agents ,Pathophysiology ,Vascular endothelial growth factor ,Psychiatry and Mental health ,Clinical Psychology ,Endocrinology ,chemistry ,Neurovascular unit ,Major depressive disorder ,Antidepressant ,Antidepressive Agent ,Female ,Psychology ,Human - Abstract
Background The vascular endothelial growth factor (VEGF) signaling, which modulates angiogenesis and neurogenesis within the neurovascular unit, might play an important role in the neuro-endocrine-immune (NEI) stress-adaptation system. Recent evidence suggests that VEGF is involved in the pathophysiology of a number of diseases including major depressive disorder (MDD) and is affected by some treatments, including antidepressants. The objective of the study was to investigate the VEGF level variations in MDD patients during antidepressant treatment with duloxetine, a relatively new SNRI. Methods A total of 30 MDD patients and 32 healthy controls were assessed using the Hamilton Depression Scale (HAM-D) and monitored for VEGF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. Results According to early clinical response to duloxetine (defined at week 6 by reduction>50% of baseline HAM-D score), the MDD patients were divided into early responders (ER) and early non-responders (ENR). During duloxetine treatment, we found an opposite trend in the VEGF levels between ER and ENR: in ER the VEGF levels significantly increased in association with clinical response at W6, while in ENR the VEGF levels significantly decreased in association with an overall clinical response at W12. Limitations Small sample size. Conclusions The opposite trends in VEGF levels, increasing in ER and decreasing in ENR, might reflect differential Norepinephrine/Serotonin effects of duloxetine on differential neurobiological backgrounds of depressive syndromes. Overall, the modulation of VEGF signaling within the neurovascular unit during antidepressant treatment could hypothetically favor the remodeling of neural circuitry, contributing to adaptive adjustment of the NEI stress-adaptation system.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.